Eye on Pharma: Catalent and Valerius to Collaborate on Biosimilars
In an announcement today, Catalent Biologics and Valerius Biopharma revealed that they will be collaborating on the development and manufacturing of Valerius’ biosimilar products.
In an announcement released today, Catalent Biologics and Valerius Biopharma revealed that they will be collaborating on the development and manufacturing of Valerius’ biosimilar products.
Through the partnership, Catalent will be responsible for providing cell line development and manufacturing processes from phase 1 clinical trials through commercial marketing of the an eventual biosimilar product.
“We selected Catalent as our development and manufacturing partner because of their technical knowledge and expertise in the current good manufacturing practices…manufacture of biosimilars, and proven track record in bringing innovative treatments to market,” said Andreas Herrmann, CEO of Valerius.
Catalent utilizes proprietary technology to create production cell lines through the transduction of targeted cells. Reportedly, the company already has produced 7 biosimilars using its technology that are available on the global market.
“We are pleased to partner with Valerius on their biologic-based therapeutics for many important indications. We look forward to supporting them in their goal of producing affordable biosimilars that will provide equal access to medicinal products,” said vice president and general manager of drug substance and bioanalytical services of Catalent Biologics, Mike Reilly.
Financial terms of the agreement were not disclosed.
This collaboration is the latest in a wave of partnerships, mergers, and acquisitions to date. Last week, Amneal Pharmaceuticals announced it will be combining efforts with Spain-based mAbxience as the exclusive US partner for a potential bevacizumab (Avastin) biosimilar. This agreement marked the third biosimilar deal licensed by Amneal.
Earlier this year, fellow biosimilar developer Mylan, in its Investor Day presentation, highlighted its own partnerships with Biocon, Momenta, and Revance, and emphasized that its strategy includes acquiring biosimilar molecules.
Also this spring, Biogen indicated that it expects to increase its stake in a partnership with Samsung BioLogics in their joint venture, Samsung Bioepis.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.
